03:31 PM EST - ProMetic Life Sciences Inc. : announced today the signature of definitive agreements for the co-development and co-exclusive commercialization, on a worldwide basis (excluding China), of a plasma-derived biopharmaceutical product targeting a rare medical condition. The deal includes the granting of manufacturing rights by ProMetic to HBI of plasma-derived biopharmaceuticals using ProMetic's proprietary PPPS(TM). The $10 million from HBI will fund the Orphan Drug's development program up to regulatory approval. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.015 at $0.12.
